Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Table 2 Non-invasive markers of hepatic fibrosis in patients observed in the study (n = 52) and included in groups treated with the sodium-glucose co-transporter-2 inhibitors or other glucose lowering drugs at baseline (T0) and after 6 mo of therapy (T1)

		T0	T1	P value
NAFLD fibrosis score (F3/4), n (%)	SGLT2-I (n = 26)	9 (34.6)	4 (15.4)	0.042
	OTHER (n = 26)	7 (26.9)	7 (26.9)
FIB-4 (F3/4), n (%)	SGLT2-I (n = 26)	11 (42.3)	6 (23.1)	0.036
	OTHER (n = 26)	7 (26.9)	7 (26.9)
AST/ALT ≥ 0.8, n (%)	SGLT2-I (n = 26)	15 (57.7)	6 (23.1)	0.001
	OTHER (n = 26)	10 (38.5)	11 (42.3)

NAFLD: Non-alcoholic fatty liver disease; FIB-4: Fibrosis-4; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; SGLT2-I: Sodium-glucose co-transporter-2 inhibitor; OTHER: Other glucose lowering drug.